Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
Adam M Kase,1 John A Copland III,2 Winston Tan1 1Mayo Clinic Florida Division of Hematology Oncology, Jacksonville, FL 32224, USA; 2Mayo Clinic Florida Department of Cancer Biology, Jacksonville, FL 32224, USACorrespondence: Adam M Kase Tel +1 904-953-0315Fax +1 905-953-2315Email kase.adam@mayo.eduA...
Main Authors: | Kase AM, Copland III JA, Tan W |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-10-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/novel-therapeutic-strategies-for-cdk46-inhibitors-in-metastatic-castra-peer-reviewed-article-OTT |
Similar Items
-
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Albert Jang, et al.
Published: (2020-11-01) -
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
by: Dhruv Bansal, et al.
Published: (2021-01-01) -
Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01) -
The new approaches to the treatment of castration- resistant prostate cancer: PARP inhibitors
by: А. А. Gritskevich, et al.
Published: (2021-06-01) -
Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
by: Sanjoy Kumar Sureka, et al.
Published: (2016-01-01)